Performance evaluation and multicentre study of a von Willebrand factor activity assay based on GPIb binding in the absence of ristocetin

Blood Coagulation and Fibrinolysis

Volumn 25, Issue 8, 2014, Pages 860-870

  Patzke, Juergen ^a   Budde, Ulrich ^b   Huber, Andreas ^c   Méndez, Adriana ^c   Muth, Heidrun ^a   Obser, Tobias ^d   Peerschke, Ellinor ^e   Wilkens, Matthias ^a   Schneppenheim, Reinhard ^d  

^a Siemens Healthcare Diagnostics   (Germany)

^b Medilys Laborgesellschaft mbH   (Germany)

^c CANTONAL HOSPITAL AARAU   (Switzerland)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e MOUNT SINAI HOSPITAL   (United States)

Author keywords

Activity; GPIb; Von Willebrand disease; Von Willebrand factor; Von willebrand factor:RCo; VWF:GPibM

Indexed keywords

GLYCOPROTEIN IB ALPHA; RISTOCETIN; VON WILLEBRAND FACTOR; DIAGNOSTIC KIT; RECOMBINANT PROTEIN; THROMBIN RECEPTOR;

ARTICLE; AUTOANALYSIS; BLOOD CLOTTING TEST; CONTROLLED STUDY; CORRELATION ANALYSIS; GAIN OF FUNCTION MUTATION; HEMATOLOGY TEST KIT; HUMAN; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MEASUREMENT PRECISION; PRIORITY JOURNAL; PROTEIN BINDING; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR ACTIVITY ASSAY; ADULT; AGED; BIOASSAY; BLOOD; CHEMICAL STRUCTURE; CHEMISTRY; CLINICAL TRIAL; DIAGNOSTIC KIT; FEMALE; GENETICS; LABORATORY AUTOMATION; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; MUTATION; REPRODUCIBILITY; STANDARDS; STATISTICAL MODEL; VON WILLEBRAND DISEASES;

ADULT; AGED; AUTOMATION, LABORATORY; BIOLOGICAL ASSAY; FEMALE; HUMANS; LIMIT OF DETECTION; LINEAR MODELS; MALE; MIDDLE AGED; MODELS, MOLECULAR; MUTATION; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; REAGENT KITS, DIAGNOSTIC; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS; RISTOCETIN; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 84927673794     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0000000000000169     Document Type: Article

References (22)

1. Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill GH, Holmberg L, et al. Update on the pathophysiology and classification of vonWillebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006;4:2103-2114.
2. Nichols W, Hultin MB, James AH, Manco-Johnson MJ, Montgomery RR, Ortel TL, et al. Von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Hemophilia 2008;14:171-232.
3. Chen D, Tange JI, Meyers BJ, Pruthi RK, Nichols WL, Heit A. Validation of an automated latex particle-enhanced immunoturbidimetric von Willebrand factor activity assay. J Thromb Haemost 2011;9:1993-2002.
4. Ahmad S, Ptashkin B, DiGiovanni C, Cines DB, Konkle BA, Cuker A. False normal von Willebrand factor activity by monoclonal antibody-based ELISA in a patient with type 2A (IID) von Willebrand disease. Thromb Haemost 2011;106:1224-1225.
5. Howard MA, Firkin BG. Ristocetin a new tool in the investigation of platelet aggregation. Thromb Diath Haemorrh 1971;26:362-369.
6. Allain JP, Cooper HA, Wagner RH, Brinkhous KM. Platelets fixed with paraformaldehyde: a new reagent for assay of von Willebrand factor and platelet aggregating factor. J Lab Clin Med 1975;85:318-328.
7. Flood VH, Gill JC, Morateck PA, Christopherson PA, Friedman KD, Haberichter SL. Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. Blood 2010;116:280-286.
8. Vanhoorelbeke K, Cauwenberghs N, Vauterin S, Schlammadinger A, Mazurier C, Deckmyn H, et al. A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factor. Thromb Haemost 2000;83:107-113.
9. Vanhoorelbeke K, Cauwenberghs N, Vandecasteele G, Vauterin S, Deckmyn H. A reliable von Willebrand factor: ristocetin cofactor enzyme-linked immunosorbent assay to differentiate between type 1 and type 2 von Willebrand disease. Semin Thromb Haemost 2002;28:161-166.
10. Federici AB, Canciani MT, Forza I, Mannucci PM, Marchese P, Ware J, Ruggeri ZM. A sensitive ristocetin co-factor activity assay with recombinant glycoprotein Ibalpha for the diagnosis of patients with low von Willebrand factor levels. Haematologica 2004;89:77-85.
11. Vanhoorelbeke K, Pareyn I, Schlammadinger A, Vauterin S, Hoylaerts MF, Arnout J, Deckmyn H. Plasma glycocalicin as a source of GPIbalpha in the von Willebrand factor ristocetin cofactor ELISA. Thromb Haemost 2005;93:165-171.
12. Piñol M, Sánchez T, Sales M, Arnout J, Van Russelt M. New automated ristocetin cofactor activity assay to distinguish type 1 and type 2 von Willebrand Disease (VWD) [Abstract No. PP-TH-635, XXII ISTH Congress]. J Thromb Haemost 2009;7(Supplement 2):1146.
13. Flood VH, Friedman KD, Gill F C, Morateck PA, Wren JS, Scott JP, Montgomery RR. Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function. J Thromb Haemost 2009;7:1832-1839.
14. Tous J, Barry RG, Arnout J, Vanrusselt M, Pascual Z, Serra J. New automated chemiluminescent VWF: Ag and VWF: RCo assays: preliminary analytical and clinical performance. J Thromb Haemost 2009;7(Suppl 2):1143; Abstract PP-TH-635 of the XXII ISTH Congress.
15. Flood VH, Gill JC, Morateck PA, Christopherson PA, Friedman KD, Haberichter SL, et al. Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD. Blood 2011;117:e67-e74.
16. Othman M. Platelet-type Von Willebrand disease: three decades in the life of a rare bleeding disorder. Blood Rev 2011;25:147-153.
17. CLSI/NCCLS. Evaluation of the linearity of quantitative measurement procedures: a statistical approach; approved guideline. CLSI/NCCLS document EP06-A. Wayne, PA: NCCLS; 2003.
18. CLSI/NCCLS. Protocols for determination of limits of detection and limits of quantitation; approved guideline. CLSI/NCCLS document EP17-A. Wayne, PA: NCCLS; 2004.
19. CLSI/NCCLS. Evaluation of precision performance of quantitative measurement methods; approved guideline-second edition. CLSI/NCCLS document EP05-A2. Wayne, PA: NCCLS; 2004.
20. International Federation of Clinical Chemistry, Scientific Committee, Clinical Section, Expert Panel on Theory of Reference Values and International Committee for Standardization in Haematology. Part 5. Statistical treatment of collected reference values. Determination of reference limits. J Clin Chem Clin Biochem 1987;25:645-656.
21. Scott JP, Montgomery RR, Retzinger GS. Dimeric ristocetin flocculates proteins, binds to platelets, and mediates von Willebrand factor-dependent agglutination of platelets. J Biol Chem 1991;266:8149-8155.
22. Lazzari MA, Sanchez-Luceros A, Woods AI, Alberto MF, Meschengieser SS. Von Willebrand factor (VWF) as a risk factor for bleeding and thrombosis. Hematology 2012;17(Suppl 1):S150-S152.